Group items tagged

High prevalence of gastric cancer is expected to propel growth of the gastric cancer therapeutics market. For instance, according to The American Cancer Society, the U.S. is estimated to record about 26,560 cases of stomach cancer and about 11,180 people will die from this type of cancer in 2021. Moreover, R&D in oral chemotherapy for the treatment of gastric cancer is also expected to aid in growth of the market. For instance, in January 2021, Ascelia Pharma AB announced the clinical development plan for Oncoral, with which the company has the opportunity to develop a novel oral chemotherapy for the treatment of gastric cancer. Risk factors for gastric cancer may include smoking and a diet of highly processed or salty foods. Thus, high number of smokers is expected to offer lucrative growth opportunities for players in the gastric cancer therapeutics market. For instance, according to the World Health Organization's, May 2020 Update, tobacco leads to over 8 million deaths each year worldwide and over 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/high-prevalence-of-gastric-cancer-and.html